NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning,
Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ONEOK, Inc.
(NYSE:OKE), ServiceNow, Inc. (NYSE:NOW), Mirati Therapeutics, Inc. (NASDAQ:MRTX), ImmunoCellular Therapeutics, Ltd (NYSE:IMUC),
United Technologies Corporation (NYSE:UTX), and USG Corporation (NYSE:USG) including updated fundamental summaries, consolidated
fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
OKE DOWNLOAD: http://Fundamental-Markets.com/register/?so=OKE
NOW DOWNLOAD: http://Fundamental-Markets.com/register/?so=NOW
MRTX DOWNLOAD: http://Fundamental-Markets.com/register/?so=MRTX
IMUC DOWNLOAD: http://Fundamental-Markets.com/register/?so=IMUC
UTX DOWNLOAD: http://Fundamental-Markets.com/register/?so=UTX
USG DOWNLOAD: http://Fundamental-Markets.com/register/?so=USG
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine
ONEOK, Inc. (NYSE:OKE), ServiceNow, Inc. (NYSE:NOW), Mirati Therapeutics, Inc. (NASDAQ:MRTX), ImmunoCellular Therapeutics, Ltd
(NYSE:IMUC), United Technologies Corporation (NYSE:UTX), and USG Corporation (NYSE:USG) on a fundamental level and outlines the
overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion,
and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers
below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as
such, important information may be missing from these samples. All information in this release was accessed
November 7, 2017. Please download the entire research report, free of charge, to ensure you are reading all relevant material
information. All amounts in millions (except per share amounts).
-----------------------------------------
ONEOK, INC. (OKE) REPORT OVERVIEW
ONEOK's Recent Financial Performance
For the three months ended September 30, 2017 vs September 30, 2016, ONEOK reported revenue of $2,906.4 vs
$2,357.9 (up 23.3%), diluted earnings per share $0.43 vs $0.43 (unchanged), and dividends per share $0.745 vs $0.615 (up 21.1%).
For the twelve months ended December 31, 2016 vs December 31, 2015, ONEOK reported revenue of $8,920.9 vs $7,763.2 (up 14.9%),
diluted earnings per share $1.66 vs $1.16 (up 43.1%), and dividends per share $2.46 vs $2.43 (up 1.2%).
To read the full ONEOK, Inc. (OKE) report, download it here: http://Fundamental-Markets.com/register/?so=OKE
-----------------------------------------
SERVICENOW, INC. (NOW) REPORT OVERVIEW
ServiceNow's Recent Financial Performance
For the three months ended June 30, 2017 vs June 30, 2016, ServiceNow reported revenue of $471.7 vs $341.3 (up
38.2%) and diluted earnings per share -$0.33 vs -$0.30. For the twelve months ended December 31, 2016 vs December 31, 2015,
ServiceNow reported revenue of $1,390.5 vs $1,005.5 (up 38.3%) and diluted earnings per share -$2.75 vs -$1.27.
To read the full ServiceNow, Inc. (NOW) report, download it here: http://Fundamental-Markets.com/register/?so=NOW
-----------------------------------------
MIRATI THERAPEUTICS, INC. (MRTX) REPORT OVERVIEW
Mirati Therapeutics' Recent Financial Performance
For the three months ended September 30, 2017 vs September 30, 2016, Mirati Therapeutics reported diluted
earnings per share -$0.65 vs -$0.97. For the twelve months ended December 31, 2016 vs December 31, 2015, Mirati Therapeutics
reported diluted earnings per share -$4.20 vs -$3.82.
To read the full Mirati Therapeutics, Inc. (MRTX) report, download it here: http://Fundamental-Markets.com/register/?so=MRTX
-----------------------------------------
IMMUNOCELLULAR THERAPEUTICS, LTD (IMUC) REPORT OVERVIEW
ImmunoCellular's Recent Financial Performance
For the three months ended June 30, 2017 vs June 30, 2016 ImmunoCellular reported diluted earnings per share
-$1.02 vs -$2.30. For the twelve months ended December 31, 2016 vs December 31, 2015, ImmunoCellular reported earnings per share of
-$7.89 vs -$5.87.
To read the full ImmunoCellular Therapeutics, Ltd (IMUC) report, download it here: http://Fundamental-Markets.com/register/?so=IMUC
-----------------------------------------
UNITED TECHNOLOGIES CORPORATION (UTX) REPORT OVERVIEW
United Technologies' Recent Financial Performance
For the three months ended September 30, 2017 vs September 30, 2016 United Technologies reported revenue of
$15,062 vs $14,354 (up 4.9%), diluted earnings per share $1.67 vs $1.78 (down 6.2%). For the twelve months ended December 31, 2016
vs December 31, 2015 UTX reported revenue of $57,244 vs $56,098 (up 2.0%) and diluted earnings per share $6.12 vs. $8.61 (down
28.9%).
To read the full United Technologies Corporation (UTX) report, download it here: http://Fundamental-Markets.com/register/?so=UTX
-----------------------------------------
USG CORPORATION (USG) REPORT OVERVIEW
USG's Recent Financial Performance
For the three months ended September 30, 2017 vs September 30, 2016, USG reported revenue of $795 vs $767 (up
3.7%), diluted earnings per share $0.46 vs $0.42 (up 9.5%). For the twelve months ended December 31, 2016 vs December 31,
2015 USG reported revenue of $3,017 vs $2,913 (up 3.6%) and diluted earnings per share $3.46 vs $6.73 (down 48.6%).
To read the full USG Corporation (USG) report, download it here: http://Fundamental-Markets.com/register/?so=USG
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world’s leading
brokerages for over a decade—and continue to be one of the best information sources for investors and investment professionals
worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA®
BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst®
(CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes
qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers.
Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit
firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries
regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail
at compliance@fundamental-markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental
Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result
from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the
material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the
publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm,
investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full
disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: andrew.duffie@fundamental-markets.com
© 2017 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a
partner network manager at partnership@fundamental-markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory
Authority, Inc.
